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Abstract: The remodeling of specific calcium-permeable ion channels is a feature of some breast
cancer subtypes. ORAI1 is a protein that forms a calcium-permeable ion channel responsible
for store-operated calcium entry (SOCE) in a variety of cell types. ORAI3, a related isoform,
is not a regulator of SOCE in most cell types. However, ORAI3 does control SOCE in many
estrogen receptor-positive breast cancer cell lines, where it also controls proliferation. ORAI1
is a well-characterized regulator of the proliferation and migration of many basal breast cancer
cells; however, the role of ORAI3 in these types of breast cancer cells remains unclear. Here, we
sought to define ORAI1 and ORAI3 expression in breast cancer cell lines of different molecular
subtypes and assess the potential role and regulation of ORAI3 in basal breast cancer cells. Our study
demonstrates that elevated ORAI1 is a feature of basal-like breast cancers, while elevated ORAI3
is a feature of luminal breast cancers. Intriguingly, we found that ORAI3 is over-expressed in the
mesenchymal subtype of triple-negative breast cancer. Given this, we assessed ORAI3 levels in the
presence of two inducers of the mesenchymal phenotype, hypoxia and epidermal growth factor
(EGF). Hypoxia induced ORAI3 levels in basal breast cancer cell lines through a pathway involving
hypoxia-inducible factor-1 alpha (HIF1α). The silencing of ORAI3 attenuated hypoxia-associated
phosphorylation of the EGF receptor (EGFR) and the expression of genes associated with cell
migration and inflammatory/immune responses in the MDA-MB-468 model of basal breast cancer.
Although elevated ORAI3 levels were not associated with survival; basal, estrogen receptor-negative
and triple-negative breast cancers with high ORAI3 and low ORAI1 levels were associated with
poorer clinical outcomes. This study defines ORAI3 as a potential fine-tuner for processes relevant to
the progression of basal breast cancers.
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1. Introduction
The remodeling of calcium (Ca2+) signaling and/or changes in the expression of specific
Ca2+-permeable ion channels occurs in a variety of cancers [1,2]. In some cases, changes in Ca2+
signaling, such as the molecular components of store-operated Ca2+ entry (SOCE) are a feature of
specific breast cancer subtypes [3]. Breast cancer is a heterogeneous disease with several molecular
subtypes including luminal A, luminal B, Her-2 enriched, claudin-low, and basal-like. The vast
majority of luminal A and B tumors express the estrogen receptor [4,5]; in contrast, most basal breast
cancers are triple negative breast cancers (TNBC) that lack expression of the estrogen, progesterone
and ERBB2 (HER2) receptors [4,5]. No targeted therapies for TNBC currently exist, making target
identification a major priority to improve the prognosis of this disease [6]. Recently, molecular
subtypes of TNBC have been defined and include Basal-Like Immune-Suppressed (BLIS), Basal-Like
Immune-Activated (BLIA), Luminal-Androgen Receptor (LAR) and Mesenchymal (MES), which may
aid our understanding of how to therapeutically target specific TNBCs [7,8]. TNBC is the most
heterogeneous classification of breast cancers, and it remains unknown if there are differences in the
Ca2+ entry pathways within TNBCs.
The canonical components of SOCE seem to be particularly important in breast cancers of the
basal molecular subtype. SOCE is initiated by the depletion of endoplasmic reticulum Ca2+ stores,
which is detected by the endoplasmic reticulum Ca2+ sensor STIM1, resulting in STIM1 mediated
activation of plasmalemmal hexameric ORAI1 channels and subsequent Ca2+ influx [9,10]. Assessment
of microarray datasets indicates that ORAI1 levels are higher in basal breast cancers compared to
non-basal [11]. Moreover, silencing and pharmacological inhibition of ORAI1 in basal/triple negative
MDA-MB-231 breast cancer cells reduces their invasiveness in vitro and in vivo [12]. However, we still
do not have a full understanding of the nature of ORAI1 overexpression in breast cancer molecular
subtypes nor the possible drivers for altered expression, such as is evident in the overexpression of
TRPV6 in ERα-negative breast cancers, which is associated with increases in gene copy number [13].
ORAI1 has been assessed in a variety of cancer models since its identification in 2006 [14], and
this has been comprehensively reviewed by other authors [15–19]. In contrast, fewer studies have
assessed its related isoform ORAI3 in cancer. ORAI3 is present only in mammals and is described as
the “exceptional” ORAI isoform [20]. Indeed, the extended length of the ORAI3 extracellular domain
may reflect distinct regulatory mechanisms for ORAI3 [20]. ORAI3 is more insensitive to inhibition
by oxidation than ORAI1, and ORAI3 silencing increases the sensitivity of human effector T helper
lymphocytes to reactive oxygen species (ROS) [21]. The potential importance of ORAI3 in the context
of external stress responses is also reflected in the increased expression of ORAI3 in the lungs of mice
after staphylococcal infection, where the reduced sensitivity of ORAI3 to ROS-mediated inhibition
may be important in immune responses [22]. Hence, ORAI3 may be of particular significance in the
tumor microenvironment where hypoxia can contribute to increased levels of ROS [23–25]. Indeed,
hypoxia in the tumor microenvironment is linked to the activation of a variety of invasive pathways
including epithelial to mesenchymal transition (EMT) [25]. However, there are no previous studies of
hypoxia effects of ORAI3 in cancer cells.
Studies assessing ORAI3 have highlighted the potential importance of ORAI3 in specific cancer
types. In some prostate cancers, disease progression seems to be associated with a switch from
ORAI1-mediated Ca2+ influx to Ca2+ influx mediated by an ORAI1/ORAI3 heteromeric channel,
due to genomic alterations in ORAI3 expression and/or tumor microenvironmental factors [26]. The
consequences of this remodeling are increased proliferation and apoptotic resistance [26]. More
recently, ORAI3 levels have been related to metastasis and poor survival in lung adenocarcinomas [27].
In the context of breast cancer, ORAI3 silencing has anti-proliferative effects on estrogen receptor-α
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(ERα)-positive MCF-7 cells in vitro and in vivo [28,29], but no effect on the anchorage-independent
growth of ERα-negative/basal/triple negative MDA-MB-231 breast cancer cells [29]. Further evidence
of association between ERα status and breast cancer, is the report of increased levels of ORAI3 in
ERα-positive breast cancer cell lines compared to ERα-negative breast cancer cell lines, the contribution
of ORAI3 to SOCE in ERα-positive breast cancer cell lines but not those which lack the ERα [30] and
the ability of ERα silencing to significantly reduce ORAI3 expression in MCF-7 cells [29]. However,
the relationship between ORAI3 levels and breast cancer subtypes has not been extensively evaluated
in clinical samples. In this study, we sought to define ORAI3 mRNA expression in breast cancers of
different molecular subtypes and compare expression profiles in relation to ORAI1 expression. The
potential role of increased gene copy number on ORAI3 and ORAI1 expression in breast cancer subtypes
was also evaluated. The sensitivity of ORAI3 expression to hypoxia was assessed in breast cancer
cells. Finally, silencing siRNAs were used to help identify possible pathways that may be regulated by
ORAI3 in an ERα-negative basal/TNBC cell line with known hypoxia-driven cellular plasticity.
2. Material and Methods
2.1. Cell Culture
The MDA-MB-468 cell line was obtained from The Brisbane Breast Bank, UQCCR, Brisbane,
QLD, Australia and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with high glucose
(Sigma-Aldrich, St Louise, MO, USA), supplemented with 4 mM L-glutamine 10% fetal bovine serum
(FBS). MDA-MB-468 cells stably expressing the GCaMP6m sensor were maintained in the media
described above with the addition of 0.5 µg/mL puromycin (Sigma-Aldrich). The HCC1569 and
MDA-MB-231 cell lines were obtained from The American Type Culture Collection (ATCC, Manassas,
VA, USA) and cultured in RPMI-1640 media (Sigma-Aldrich) and DMEM respectively, both with 10%
FBS. The PMC42LA cell line was obtained from Dr. Leigh Ackland, Deakin University, Melbourne,
Australia [31,32], and maintained in RPMI-1640 media with 10% FBS. Cells were maintained in
37 ◦C and 5% CO2 in a humidified incubator. For hypoxia experiments, 24 h post plating cells were
serum starved (0.5% FBS) for 24 h and placed in a hypoxic incubator (1% O2, 5% CO2 and 94% N2)
for periods stated in the results. For the EGF experiment, 24 h post serum reduction, cells were
treated with 50 ng/mL EGF (E9644; Sigma-Aldrich) for 24 h prior to RNA isolation. Cell lines were
routinely tested for mycoplasma using MycoAlert kit (Lonza, Basel, Switzerland) and validated by
STR profiling using The GenePrint® 10 System (Promega, Madison, WA, USA) at QIMR Berghofer,
Brisbane, QLD, Australia.
2.2. Real-Time RT-PCR
Total RNA was isolated and purified using a RNeasy Plus Mini Kit (74134; Qiagen). Reverse
transcription was performed using the Omniscript RT Kit (205111, Qiagen, Hilden, Germany).
The resulting cDNA was amplified using TaqMan Fast Universal PCR Master Mix (4352042; Life
Technologies, Carlsbad, CA, USA) and TaqMan gene expression assays in a StepOnePlus Real-Time
PCR system (Life Technologies). Relative target mRNA levels were calculated using the comparative CT
(∆∆CT) method and results were normalized to the ribosomal 18S sRNA. The specific Taqman real-time
assays used in this study are as follow: 18s ribosomal RNA (4319413E), Snail (Hs00195591_m1), Twist
(Hs00361186_m1), N-cadherin (Hs00983062_m1), CD24 (Hs02379687_s1), CD44 (Hs01075861_m1),
ORAI1 (Hs00385627_m1), ORAI2 (Hs00259863_m1), ORAI3 (Hs00743683_s1), ID1 (Hs03676575_s1),
TREM1 (Hs00218624_m1) and PGF (Hs00182176_m1).
2.3. Immunoblotting
MDA-MB-468 cells were lysed using protein lysis buffer containing IGEPAL (1% v/v), sodium
deoxycholate (0.5% w/v), Tris (50 mM), NaCl (100 mM), and protease and phosphatase inhibitors.
Protein concentrations were determined based on the Bradford method using the colorimetric Protein
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Assay Dye Reagent (500-0006, Bio-Rad, Hercules, CA, USA). Samples were resolved on NuPAGE
4–12% Bis-Tris Protein Gels (Invitrogen, Carlsbad, CA, USA) or Mini-PROTEAN TGX stain-free precast
gels (Bio-Rad) and transferred to polyvinylidene difluoride membranes. Proteins were detected using
primary antibodies against EGFR (2232, Cell Signaling, Danvers, MA, USA), phospho-EGFR (Tyr1173;
4407, Cell Signaling), vimentin (V6389, Sigma-Aldrich), HIF-1α (610958, BD Bioscience, San Jose,
CA, USA) and β-actin (A5441, Sigma-Aldrich) and horseradish peroxidase-conjugated secondary
antibodies goat-anti-mouse (170-6516, Bio-Rad) and goat-anti-rabbit (170-6516, BioRad). Primary
antibodies were incubated with membranes overnight at 4 ◦C except for β-actin antibody, which
was incubated for 1 h at room temperature. Secondary antibodies were incubated for 1 h at room
temperature. Images were obtained using a Bio-Rad VersaDoc or ChemiDoc Imaging System and
quantified using Quantity One (version 4.6.7, Bio-Rad) or Image Lab Software (version 5.2.1, Bio-Rad).
2.4. siRNA-Mediated Silencing
Cells were seeded at 1 × 104 (for 24 h hypoxia), 6 × 103 (for 48 h hypoxia) and 3.5 × 103 (for 72 h
hypoxia) per well in 96-well plates. 24 h post seeding, DharmaFECT4 Transfection Reagent (0.1 µL
per well) and Dharmacon ON-TARGETplus SMARTpool siRNAs (Thermo Scientific, Waltham, MA,
USA), which are a mixture of four siRNAs providing advantages in both specificity and potency
of gene silencing, were used for silencing ORAI3 (L-015896-00), HIF-1α (L-004018-00) and HIF-1β
(L-007207-00). Non-targeting siRNA (siNT; D-001810-10) was used as control treatment.
2.5. Measurement of Cytosolic Free Ca2+
Fluorometric Imaging Plate Reader (FLIPRTETRA, Molecular Devices, Sunnyvale, CA, USA) and
the PBX no-wash Ca2+ Assay Kit (640,175, BD Biosciences) were used to assess cytosolic free Ca2+
([Ca2+]CYT) in MDA-MB-468 cells. Cells were seeded at a density of 6 × 103 per well in 96-well
CellBIND plates (Corning Costar, MA, USA). Post plating (24 h), ORAI3 was siRNA-silenced as
described above. Two days after silencing, cells were serum starved (0.5% FBS) for 24 h and
subsequently placed in a hypoxia incubator for 48 h. Ca2+ measurement during the SOCE was
performed as previously described [33,34]. ScreenWorks Software (v2.0.0.27, Molecular Devices) was
used to analyse data, and response over baseline was evaluated as a relative measure of [Ca2+]CYT.
2.6. Cell Migration Assay
Cell motility was assessed using collagen matrices and live cell imaging. Collagen coated plates
were prepared by adding 50 µL of a collagen mixture comprising 10× PBS (8% v/v), DMEM (24% v/v),
collagen type I from bovine skin (final concentration 2 mg/mL; C4243, Sigma-Aldrich), adjusted to
physiological pH with 1 M NaOH, to 96-well cell culture plates. Plates were then incubated at 37 ◦C,
5% CO2 for 1 h prior to cell seeding at a density of 1000 cells per well. ORAI3 was siRNA-silenced
24 h post seeding as described above but with 0.5 µL per well DharmaFECT4 Transfection Reagent.
Cells were serum starved (0.5% FBS) for 48 h after silencing for 24 h, and were then placed on the stage
of a JuLiTM Stage Live Cell Imaging System (NanoEnTek Inc. Seoul, South Korea) contained within
a hypoxia incubator. Cell motility was assessed by capturing bright field images with 4× objective
from the centre of wells every 15 min, starting from 72 h post exposure to hypoxia for a period of
12 h (between 72–84 h in hypoxia). Single cell tracking was performed using ImageJ 1.49q software
(NIH, Bethesda, MD, USA, website: https://imagej.nih.gov/ij/ (accessed on 10 March 2016) and cell
movement was calculated and illustrated with Chemotaxis and Migration Tool V2.0 (Ibidi, Munich,
Germany). Strict criteria were applied for the exclusion of cells that were dying, dividing or moving
out of the field of view during the period of assessment.
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2.7. Development of MDA-MB-468-GCaMP6m Cell Line
GCaMP6m was amplified from pGP-CMV-GCaMP6m (a gift from Dr. Douglas Kim, Addgene
plasmid #40754) and cloned with BamHI and NotI restriction enzymes into pCDH-EF1-FHC lentiviral
vector (a gift from Dr. Richard Wood, Addgene plasmid #64874). The sequence of GCaMP6m was
fully verified by Sanger sequencing. Lentiviral vectors pCMV-VSV-G, pCMV-dR8.2 dvpr (a gift
from Dr. Bob Weinberg, Addgene plasmids #8454 and #8455) and pCDH-EF1-FHC-GCaMP6m were
transfected into HEK293T cells using Lipofectamine 3000 (Thermo Scientific, Waltham, MA, USA)
as per the manufacturer’s protocol. Post-transfection (48 h) the viral supernatant was collected and
used to transduce MDA-MB-468 cells, in the presence of 8 µg/mL polybrene (Merck, Darmstadt,
Germany). After 48 h, cells were treated with 1 µg/mL of puromycin (Sigma-Aldrich). Transduced
MDA-MB-468-GCaMP6m cells were sorted into single colonies via a Beckman Coulter MoFlo Astrios
EQ, expanded, and validated as previously described [35].
2.8. Assessment of Spontaneous Ca2+ Transients
MDA-MB-468-GCaMP6m cells were seeded at a density of 6 × 103 cells per well in 96-well
black-walled imaging plates (Corning Falcon) and underwent ORAI3 silencing and hypoxic treatment
as described above. Following hypoxic exposure, media was changed to physiological salt solution
(PSS, 5.9 mM KCl, 1.4 mM MgCl2, 10 mM HEPES, 1.2 mM NaH2PO4, 5 mM NaHCO3, 140 mM
NaCl, 11.5 mM glucose, 1.8 mM CaCl2, pH 7.3) and cells were imaged every 2 s for 60 s using a
10× objective and an automated epi-fluorescent microscope ImageXpress Micro (Molecular Devices).
Excitation and emission wavelengths were 472/30 nm and 530/35 nm, respectively. Automated
image segmentation using MetaXpress Software (v. 6.2.3.733, Molecular Devices), was conducted
as previously described [35]. Responses of individual cells were analysed for peaks and troughs in
relative GCaMP6m fluorescence intensity, with spontaneous Ca2+ activity considered to have occurred
if a peak was a minimum of 1.5% greater in relative fluorescence intensity than the preceding trough.
2.9. ORAI3 Promoter Analysis
Histone methylation data was sourced from ENCODE through the IGV browser [36,37]. Phastcons
and CpG islands were also accessed through the IGV browser from the data registry of the Broad
Institute [37]. ChIP-Seq data for HIF1α and HIF1β was sourced through the Gene Expression Omnibus
(GSE59937 [38]). The HIF motif was published as RCGTGM [39]. The IGV snapshot was taken on the
combined data using IGV for Mac Desktop v2.3.81 [37].
2.10. Analysis of ORAI1 and ORAI3 Expression in Breast Tumors
RNA-Seq data for the TCGA dataset [40] was sourced cBioPortal for Cancer Genomics [41,42] and
includes 1100 tumors, 140 Basal-like (Basal), 67 HER2-enriched (HER2), 420 Luminal A (LumA), 194
Luminal B (LumB), 24 Normal-Like (N-Like) and 255 not yet classified tumors. RNA-Seq expression
data was downloaded as RNA-Seq by expectation maximisation (RSEM [43]), log2 transformed and
graphed using Graphpad Prism 7 (v7.0b for Mac). For generation of the heat-map, expression of
ORAI1, ORAI3 and the relevant molecular markers was mean-centered and hierarchically clustered in
Multiple Experiment Viewer (MeV [43]) via Manhattan-based average-linkage clustering.
Copy number alterations (CNA) were sourced from TCGA as above but include fewer samples
with 838 tumors, 136 Basal-like (Basal), 69 HER2-enriched (HER2), 415 Luminal A (LumA), 194
Luminal B (LumB) and 24 Normal-Like (N-Like). GISTIC [44] CNA were pre-calculated by the TCGA
consortium and numbers correspond to: −2 = homozygous deletion, −1 = hemizygous deletion,
0 = neutral/no change, 1 = gain and 2 = high level amplification.
Expression levels for the TNBC subtypes was sourced from R2 Genomics Analysis and
Visualization Platform (http://r2.amc.nl). The Brown TNBC breast tumor cohort [7] was used to
asses ORAI3 expression within TNBC subtypes. The four subtypes consisted of 198 tumors in total,
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including 54 Basal-like immune activated (BLIA), 60 Basal-like immune-suppressed (BLIS), 37 Luminal
androgen receptor (LAR) and 47 mesenchymal (MES). Graphed are the normalized array probe values.
2.11. Patient Survival Analysis
Analysis of patient survival was carried out using the online Kaplan-Meier Plotter tool [45].
Survival was stratified using the ‘Auto select best cutoff’ and cohorts selected as ERα-negative
(ERα-), Basal: ER- and HER2-negative, TNBC: ERα-, HER2 and progesterone receptor negative
(PR-). For analysis of ORAI3/ORAI1 ratios stratifying patient survival, ORAI1 was assessed in inverse.
Kaplan-Meier Plotter combined the average expression of ORAI3 with the inverse expression for
ORAI1, so that a tumor with high ORAI3 must have low ORAI1. This is done with the option “Use
multigene classifier,” then the average expression of both probes and the “invert” option on for ORAI1.
Expression cut-offs are automatically determined by the tool. Pietenpol TNBC subtypes were defined
in Lehmann et al. 2011 [8]. Patient numbers within the high and low expression groups are indicated
below each graph. Hazard ratios (HR) with 95% confidence intervals and log-rank p-values are
indicated on each graph. Affymetrix probes used were, 226531_at: ORAI1 and 221864_at: ORAI3.
MedCalc (version 12.7, Ostend, Belgium) was used to calculate multivariate and univariate
Cox proportional hazard regressions based on gene expression and clinical traits. Receiver operator
characteristic (ROC) curves were generated for expression of ORAI1, ORAI2, ORAI3 and MKI67 and
expression cut-offs for ‘high’ and ‘low’ chosen based on the maximum deviation from the ‘random
guess’ line. Lymph node status was designated as negative (−) or positive (+, ≥1 node infiltrated at
time of surgery). Tumor grade and stage were sourced from METABRIC [46]. Tumor size categories
were as follows T1 ≤ 20mm, T2 ≥ 20 mm and < 50 mm and T3 ≥ 50 mm.
2.12. RNA Sequencing Analysis
Library preparation and sequencing were performed by the IMB Sequencing Facility, University
of Queensland, St Lucia, QLD, Australia. mRNA integrity was assessed on an Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA), and were of high quality (RNA integrity numbers [RIN]
of 8.7–9.2). mRNA was converted to sequencing libraries using TruSeq Stranded Total RNA Sample
Prep Kit (Illumina™, San Diego, CA, USA), and sequenced on a NextSeq 500 using high output v1
chemistry and single-end 76bp reads, resulting in >32 million reads per replicate. Reads were mapped
against the reference genome (UCSC hg19) using STAR [47], with >26 million uniquely mapped reads
per replicate. Gene-level counts were generated using htseq-count in the HTSeq python package [48]
with the UCSC annotation, and differential expression was detected using the edgeR [49] packages in
R. These data have been deposited in Gene Expression Omnibus (accession number GSE107692.
2.13. Statistical Analysis
GraphPad Prism Version 7.00 for Windows, GraphPad Software (La Jolla, CA, USA) was used for
statistical analysis. Specific statistical tests used for each experiment are described in the corresponding
figure legend.
3. Results
3.1. ORAI1 and ORAI3 in Breast Cancer Molecular Subtypes
To define levels of ORAI1 and ORAI3 in breast cancer molecular subtypes, we assessed RNA
sequencing (RNA-Seq) data from the TCGA breast cancer database (845 tumors). Figure 1A shows
breast tumors stratified by expression of molecular markers, clustering PAM50 subtypes. As expected,
breast cancers of the basal molecular subtype had low levels of the ER and PR and higher levels of the
epidermal growth factor receptor (EGFR). Consistent with reports from microarray data indicating
higher levels of ORAI1 in basal breast cancers compared to non-basal [11], our assessment of five
intrinsic PAM50 molecular subtypes showed higher levels of ORAI1 in basal breast cancers compared
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to HER2-enriched, Luminal A, Luminal B and Normal-like subtypes (Figure 1A), with significantly
higher levels of ORAI1 in basal breast cancers compared to all other molecular subtypes (Figure 1(Bi)).
The mechanism for elevated ORAI1 in basal breast cancers is unlikely to involve increases in ORAI1
gene copy number, since copy number variances did not follow the same trend as mRNA levels
(Figure 1(Ci)). Consistent with the reported lower levels of ORAI3 in ER-negative breast cancer cell
lines, breast cancers with low levels of ORAI3 were most evident in basal breast cancers (Figure 1A)
and basal breast cancers had significantly lower levels of ORAI3 than the other molecular subtypes
(Figure 1(Bii)). Copy number variance analysis indicated that the luminal molecular subtypes (which
overlap with ERα-positive breast cancers) had a much higher proportion of breast cancers with ORAI3
gain or high gain than the basal molecular subtype (Figure 2(Cii)) and hence this may be a mechanism
for elevated ORAI3 levels in these subtypes. Given that gains in ORAI3 gene copy number were
also evident in the basal subtype (Figure 1(Cii)), and some basal breast cancers were associated with
high levels of ORAI3 (Figure 1(A,Bii)), we assessed if ORAI3 levels were elevated in any of the TNBC
molecular subtypes. This analysis indicated that ORAI3 levels were significantly higher in both the
MES and LAR triple negative subtypes compared to those of the BLIA and BLIS subtypes (Figure 1D).Cancers 2019, 11, 208 8 of 21 
 
Figure 1. ORAI1 and ORAI3 are differentially expressed and amplified in breast cancer. (A) RNA-Seq 
gene expression for ORAI1, ORAI3 and commonly used molecular markers of breast cancer subtypes. 
Displayed above the heatmap are the PAM50 molecular subtypes. RNA-Seq data is log2 transformed 
RSEM and mean-centered, then clustered via Manhattan-based average-linkage. (B) RNA expression 
of ORAI1 (i) and ORAI3 (ii) within each of the PAM50 molecular subtypes. Subtypes were compared 
to the basal-like tumors and significance assessed via a one-way ANOVA with multiple comparisons 
(p-values are ** ≤0.01, **** ≤ 0.0001). (C) GISTIC copy number analysis for ORAI1 (i) and ORAI3 (ii) 
across the PAM50 molecular subtypes. Shown is the percentage of tumors within each subtype and 
the CNV. Tumor RNA-Seq and CNV sourced from TCGA. Basal-like (Basal), HER2-enriched (HER2), 
Luminal A (LumA), Luminal B (LumB) and normal-like (N-Like). (D) Expression for ORAI3 within 
the TNBC subtypes as determined by Brown et al. [7]; Basal-Like Immune-Suppressed (BLIS), Basal-
Like Immune-Activated (BLIA), Luminal-Androgen Receptor (LAR) and Mesenchymal (MES). Data 
sourced from Brown et al. [7] via R2 Genomics Analysis and Visualization Platform. ns = not 
significant (p ≥ 0.05), ** p < 0.01, **** p < 0.0001, (one-way ANOVA, with Tukey’s multiple 
comparisons). 
Figure 1. Cont.
Cancers 2019, 11, 208 8 of 20
Cancers 2019, 11, 208 8 of 21 
 
Figure 1. ORAI1 and ORAI3 are differentially expressed and amplified in breast cancer. (A) RNA-Seq 
gene expression for ORAI1, ORAI3 and commonly used molecular markers of breast cancer subtypes. 
Displayed above the heatmap are the PAM50 molecular subtypes. RNA-Seq data is log2 transformed 
RSEM and mean-centered, then clustered via Manhattan-based average-linkage. (B) RNA expression 
of ORAI1 (i) and ORAI3 (ii) within each of the PAM50 molecular subtypes. Subtypes were compared 
to the basal-like tumors and significance assessed via a one-way ANOVA with multiple comparisons 
(p-values are ** ≤0.01, **** ≤ 0.0001). (C) GISTIC copy number analysis for ORAI1 (i) and ORAI3 (ii) 
across the PAM50 molecular subtypes. Shown is the percentage of tumors within each subtype and 
the CNV. Tumor RNA-Seq and CNV sourced from TCGA. Basal-like (Basal), HER2-enriched (HER2), 
Luminal A (LumA), Luminal B (LumB) and normal-like (N-Like). (D) Expression for ORAI3 within 
the TNBC subtypes as determined by Brown et al. [7]; Basal-Like Immune-Suppressed (BLIS), Basal-
Like Immune-Activated (BLIA), Luminal-Androgen Receptor (LAR) and Mesenchymal (MES). Data 
sourced from Brown et al. [7] via R2 Genomics Analysis and Visualization Platform. ns = not 
significant (p ≥ 0.05), ** p < 0.01, **** p < 0.0001, (one-way ANOVA, with Tukey’s multiple 
comparisons). 
Figure 1. R I1 and I3 are ifferentially expressed and a plified in breast cancer. (A) RNA-Seq
gene expression for ORAI1, R I3 and co only used olecular arkers f r st c c r s t s.
Displayed above the heatmap are the PAM50 molecular subtypes. RNA-Seq data is log2 transformed
RSE and mean-centered, then clustered via Manhattan-based average-linkage. (B) RNA expression
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50 ng/mL) treatment in MDA-MB-468 cells (B) mRN expression of ORAI1, ORAI2 and ORAI3
after hypoxia (24 h, 1% O2) in MDA-MB-468 breast cancer cells compared to cells maintained in
normoxia. (C) Inductio of ORAI3 expression after hypoxia (24 h) in HCC1569, (D) MDA-MB-231 and
(E) PMC42LA breast cancer cells. (F) Assessment of ORAI3 expression in breast (MCF7), colon (HT29)
and prostate (Du145) after xposure of cells to n rmoxia (time-point 0 h) and different times of severe
hypoxia (0% O2 for 1, 2, 4, 8, 12, 16 and 24 h, respectively) extracted from the publicly available data [47]
using the R2 gen mics analysis platform. (G) confirmation of siRNA-mediated Orai3 silencing and
(H) FLIPR traces (left) and quantification (right) of the mean [Ca2+]CYT levels uring store-op rated
Ca2+ entry with ORAI3 silencing (siORAI3) and non-targ ting siRNA control ( iNT) in MDA-MB-468
cells xposed to 48 h hypoxia. I) Spontaneous Ca2+ transients in MDA-MB-468 cells expressing
GCaMP6m following ORAI3 silencing (siORAI3) and 48 h exposure to hypoxia. Ca2+ transient in
20 individual cells unbiasedly sele ted from a single well following silencing of non-targeted siRNA
control (I), or ORAI3 (J). Highlighted lines repres nt xamples of cel s exhibiting spontan ou Ca2+
activity. (K) Percentage of cells exhibiti g spontaneous Ca2+ activity. (L) Stratification of cells by
number of Ca2+ transients in 60 s. ns = not significant (p ≥ 0.05), * p < 0.05, ** p < 0.01, *** p < 0.001
(unpaired t-test), n = 3, mean ± SD.
3.2. Hypoxia Induces ORAI3 Expression
Since ORAI3 is significantly up-regulated in the TNBC cell MES subtype, compared to BLIS and
BLIA triple-negative breast cancer cell subtypes, we assessed the effect of two different epithelial to
mesenchymal transition (EMT) inducers on the expression of ORAI3 in triple negative, basal-like
MDA-MB-468 breast cancer cells. The EMT inducer in this model, epidermal growth factor
(EGF) [50,51], did not increase ORAI3 levels (Figure 2A) and instead a significant reduction in the
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level of ORAI3 was observed. In contrast, the other EMT inducer assessed, hypoxia [52], significantly
elevated levels of ORAI3, with no increases in the related isoforms ORAI1 and ORAI2 (Figure 2B).
ORAI3 levels increased in two other basal-like breast cancer cell lines (HCC1569 and MDA-MB-231)
and the EMT breast cancer cell line model PMC42LA, under hypoxic conditions (Figure 2C–E).
Assessment of a publicly available microarray dataset [53], showed that increases in ORAI3 were
also evident in ERα-positive MCF-7 breast cancer cells, HT29 colon cancer cells and Du145 prostate
cancer cells proportionate to increased exposure to hypoxia (Figure 2F). In contrast, ORAI1 and
ORAI2 were not consistently up-regulated with hypoxia in these cell lines (Figure S1). Given the
reports of ORAI3 contribution to SOCE in ERα-positive breast cancer cell lines with high levels of
ORAI3 [30], we assessed whether ORAI3 contributed to SOCE in MDA-MB-468 cells after its induction
by hypoxia. ORAI3 silencing (Figure 2G) did not reduce SOCE in MDA-MB-468 cells after hypoxia
(Figure 2H), indicating that ORAI3 did not function as a SOCE mechanism in this model of hypoxia.
To assess possible subtle effects on [Ca2+]CYT signals, the effect of ORAI3 silencing during hypoxia on
spontaneous [Ca2+]CYT oscillations, as previously described in MDA-MB-468 breast cancer cells [54],
was also evaluated. No significant effect on this parameter was observed (Figure 2I–L), suggesting that
ORAI3 may regulate highly localized Ca2+ changes and/or [Ca2+]CYT only at specific times of hypoxia
that could not be assessed in our studies.
3.3. HIF1α Controls the Hypoxic Expression of ORAI3
The potential mechanism for ORAI3 up-regulation with hypoxia was first assessed via analysis of
the promotor region of the ORAI3 gene. We defined the ORAI3 promoter region by the presence of CpG
islands, high conservation and enrichment of H3K4me3 and H3K27ac in normal human mammary
epithelial cells (HMECs). Binding motifs for the hypoxia response regulators and transcription
factors HIF1α and HIF1β were present in the ORAI3 promotor in MCF7 cells indicating an ability
for HIF1 factors to bind in breast cancer cells (Figure 3A). Silencing of HIF1α or HIF1β (Figure 3B,C),
demonstrated that hypoxia-mediated ORAI3 induction was mediated by HIF1α and not HIF1β
(Figure 3D,E). However, ORAI3 silencing suggested that ORAI3 is not a regulator of HIF1α after
hypoxic exposure in MDA-MB-468 Basal-A triple negative breast cancer cells (Figure 3F,G). Given the
induction of ORAI3 by hypoxia and the up-regulation of ORAI3 in the MES TNBC molecular subtype,
we assessed the effects of ORAI3 silencing on the induction of EMT markers by hypoxia. Hypoxia
produced robust induction of vimentin protein expression, but these changes were insensitive to
ORAI3 silencing (Figure 4A). Similarly, ORAI3 silencing had no significant effect on hypoxia-mediated
changes in mRNA levels of the EMT markers Snail, Twist, N-Cadherin, CD44/CD24 ratio (Figure 4B).
Combined with the inability of another EMT inducer EGF to promote ORAI3 expression, these
results suggest that ORAI3 is not a ubiquitous regulator of EMT. We therefore assessed another
consequence of hypoxia in this model, phosphorylation of EGFR [53]. ORAI3 but not ORAI1 silencing
significantly reduced hypoxia-induced increases in EGFR phosphorylation, although ORAI1 silencing
was close to significance (p value of 0.0546) (Figure 4C). Due to the potential role for EGFR activation
on cell migration [55,56], we assessed the consequences of ORAI3 silencing on the migration of
MDA-MB-468 cells during hypoxia using collagen matrices and live cell imaging. ORAI3 silencing
had no significant effect on the migration of MDA-MB-468 breast cancer cells under these hypoxic
conditions (Figure 4D,E), although there was a trend for an increased proportion of cells with low
levels of migration (Figure 4E).
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Figure 3. Hypoxia-induced Orai3 up-regulation is HIF1α dependent. (A) The ORAI3 genomic region 
on human chromosome 16. Displayed are the histone modifications (human m epithelial cells, HMEC) 
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indicative of active promoters, conservation (Phastcons), CpG islands, HIF1 binding (MCF7 cells)
and HIF motifs. Confirmation of HIF1α (B) and HIF1β (C) siRNA-mediated silencing and the effect
of HIF1α (D) and HIF1β (E) silencing (**** p < 0.0001, unpaired t-test) on the induction of ORAI3
by hypoxia in MDA-MB-468 cells. (F) Representative immunoblot and (G) densitometry analysis of
the effect of ORAI3 silencing on hypoxia-mediated increases of HIF1α protein in MDA-MB-468 cells
compared to NT siRNA in normoxia and hypoxia. ns = not significant (p ≥ 0.05), * p < 0.05, ** p < 0.01,
*** p < 0.001 (one-way ANOVA, with Bonferroni’s multiple comparisons), n = 3, mean ± SD.
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Figure 4. Effect of ORAI3 silencing on the levels of hypoxia-induced expression of EMT markers, EGFR
activation and cell migration of MDA-MB-468 breast cancer cells. (A) Representative immunoblot (left)
and densitometry analysis (right) of the effect of ORAI3 and ORAI1 silencing on hypoxia-induced
vimentin protein expression and (B) the effect of ORAI3 silencing on the mRNA expression of key
hypoxia-induced EMT markers in MDA-MB-468 breast cancer cells. (C) Representative immunoblot
(left) and densitometry analysis (right) of the effect of ORAI3 and ORAI1 silencing on the total levels of
EGFR protein and hypoxia-induced EGFR phosphorylation. ns = not significant (p ≥ 0.05), * p < 0.05, **
p < 0.01, *** p < 0.001, **** p < 0.0001, (one-way ANOVA, with Tukey’s multiple comparisons), n = 3,
mean± SD. (D) Representative spatial plot of all NT control- and ORAI3-silenced cells from one well of
the same experiment (left) and quantitative analysis of the distance travelled by 15 randomly selected
cells from three independent experiments (5 cells from each experiment). (E) Quantitative analysis of
the percent of cells in each experiment from three independent experiments that travelled less than
40 µm. Total number of cells from three independent experiments analyzed were 95 and 80 cells for
siNT and siORAI3, respectively. Cell migration was analysed in hypoxic conditions over a period of
12 h after exposing cells to 72 h hypoxia. ns = not significant (p ≥ 0.05) (Mann-Whitney U-test), n = 3,
mean ± SD.
3.4. ORAI3 Is Involved in the Hypoxic Regulation of Genes Associated with Cell Migration and
Inflammatory/Immune Responses
To assess the potential role of ORAI3 on responses to hypoxia, RNA-Seq was conducted comparing
gene expression under conditions of hypoxia with and without ORAI3 silencing. Gene ontology
of differentially expressed genes demonstrated that ORAI3 silencing led to the alterations in the
expression of genes affecting migration and inflammatory/immune responses (Figure 5). There was
a significant decrease in the activity of 21 annotated functions with ORAI3 silencing (most of which
related to cell migration and inflammatory/immune responses); In contrast there were no functions
that increased with ORAI3 silencing during hypoxia (Table S1). Using real time RT-PCR, we further
assessed specific targets from the gene sets associated with the migration and immune pathways
that were reduced by ORAI3 silencing at both the 48 h and 72 h hypoxia time-points. Three of these
assessed genes were significantly induced by hypoxia; Inhibitor of Differentiation 1 (ID1), Triggering
Receptor Expressed on Myeloid cells 1 (TREM-1) and Placental Growth Factor (PGF) (Figure 6). At 48 h,
there was a trend for ORAI3 silencing to attenuate induction of ID1 and TREM-1 and ORAI3 silencing
significantly reduced hypoxic induction of PGF. These data support the general conclusion that ORAI3
silencing may remodel the expression of genes involved in migration and immune pathways.
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Figure 5. Next generation sequencing data suggesting ORAI3 silencing reduces the expression of genes
associated with cell migratory and inflammatory/immune responses. Networks of genes associated
with biological functions (nodes) that were significantly altered with ORAI3 siRNA-mediated silencing
after hypoxia (1% O2, 72 h), identified using Ingenuity Pathways Analysis. Suppressed biological
functions are represented in blue nodes. Only biological functions with a z-score below −2.3 are shown
(refer to Table S1). No processes were augmented. Biological functions related to a same category were
manually circled and labelled with cell migration or inflammatory/immune responses.
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To further explore the role of ORAI3 in the context of basal breast cancers, patient survival
was stratified based on ORAI3 gene expression using KM Plotter cohorts. ORAI3 levels were not
an indicator of poorer prognosis as assessed by relapse free survival (RFS) in basal breast cancers
(Figure 7A), instead ORAI3 levels were actually associated with improved RFS. ORAI3 levels were not
associated with RFS in ERα-negative and TNBC breast cancers (which have a significant overlap with
the basal molecular subtype [5]; Figure 7B,C). Given the reported importance of the balance between
ORAI3/ORAI1, in the context of a more proliferative phenotype in prostate cancer cells [26], and our
identification that some basal breast cancers had high ORAI3 but low ORAI1 levels (Figure 1A), we
compared RFS in breast cancers with high ORAI3/low ORAI1 with other breast cancers. Breast cancers
with high ORAI3/low ORAI1 were associated with poorer RFS in basal, ERα-negative and TNBCs,
and low ORAI3/high ORAI1 associated with good outcome (Figure 7D–F). Assessment of the TNBC
subtypes [8], identified that high ORAI3/low ORAI1 was also associated with significantly poorer
RFS, in the basal like-1, mesenchymal and mesenchymal stem-like TNBC subtypes (Figure S2), but no
significant relationship was observed in other TNBC subtypes (Figure S2). Our analysis also showed
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that within basal and ER-breast cancers, higher levels of ORAI1 were associated with better relapse
free survival in patients (Figure S3). In contrast to the ORAI1/ORAI3 ratio in TNBC (Figure 7F), ORAI1
levels were not significantly associated with patient RFS in TNBC (Figure S3).Cancers 2019, 11, 208 15 of 21 
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Given the significant association between ORAI3 and patient prognosis we tested its utility against
commonly used clinical markers of patient outcome (Table S2). In this analysis and cohort, high levels
of ORAI3 alone rather than a high ORAI3/low ORAI1 was linked to a to poorer prognosis as was
ORAI2. In this analysis there was no association between ORAI1 and prognosis.
4. Discussion
Alterations in Ca2+ influx vi ORAI channels d/or the remodeling of their expression has
been identifi d in several cancers includi g breast, prostate, lung nd colon [26,57–59]. The nature
and consequences of this remodeling can differ between cancer types. For example, i some prostate
cancer cells, reduced ORAI1-mediated Ca2+ influx occurs and may bestow resistanc to some ap ptotic
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appea s to contribute to migration and proliferation pathw ys [60]. Although OR I1 silencing studies
have indicat d that ORAI1 is a contributor to the prolifer tion and inva iveness of b th basal and
non-basal breast cancer cells in vitro, report of increased ORAI1 mRNA levels in basal compared t
non-basal breast cancers suggested t at ORAI1 may make a greater contribution to th e functions
in breast cancer ubtypes [11]. Our analysis of clinical amples from the TCGA database shows that
ORAI1 levels are significantly higher in patients with basal breast cancers compared to all other breast
cancer molecular subtypes. How v r, this does not seem related to increases in ORAI1 gene region, as
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ORAI1 gene copy number was higher in the luminal and HER2 molecular subtypes compared to those
of the basal molecular subtype. Hence, further studies are required to define the mechanism by which
ORAI1 levels are elevated in basal breast cancers.
In contrast to ORAI1, the enrichment of ORAI3 in clinical breast cancer samples is largely
unexplored. However, detailed in vitro studies using human breast cancer cell lines with different
ERα expression status show that ORAI3 expression is ERα sensitive and that ORAI3 levels are greater
in ERα-positive breast cancer cell lines compared to those that are ERα-negative [29,30]. These cell
line-based studies predict that ORAI3 levels should be low in breast cancers of the basal molecular
subtype, due to their extensive overlap with breast cancers that are ERα-negative [4,5]. Indeed, our
data showed that ORAI3 levels are significantly lower in basal breast cancers compared to all other
molecular subtypes. Our analysis also suggests that in addition to the previously defined potential for
the ERα to contribute to ORAI3 expression in breast cancer cells, overexpression of ORAI3 in some
breast cancers may be a consequence of increased gene copy number. Indeed, over 50% of breast
cancers of the luminal A subtype had a gain or high gain in ORAI3 gene copy number. Hence, there
may be multiple drivers for the up-regulation of ORAI3 in ERα-positive breast cancers, which include
the ERα itself and increased copies of the ORAI3 gene region.
As discussed above, ORAI3 levels were significantly lower in basal breast cancers overall; however,
ORAI3 levels were high in some basal breast cancers, and we observed significantly higher ORAI3
levels in TNBCs of the MES and LAR molecular subtypes. These data collectively suggested that
ORAI3 levels may be inducible under certain conditions in cancer cells. Indeed, our studies show that
ORAI3 is induced in a variety of cancer models by hypoxia. In the case of MDA-MB-468 breast cancer
cells, hypoxia-induced induction of ORAI3 is mediated by HIF1α, placing ORAI3 alongside TRPC1 as
a HIF1α-inducible ion channel in this model [61,62]. However, in contrast to TRPC1, ORAI3 silencing
did not suppress HIF1α induction by hypoxia, demonstrating that regulation is not bidirectional in the
context of hypoxia, HIF1α and ORAI3. Despite the increases in hypoxia-induced ORAI3 expression
in MDA-MB-468 ERα-negative breast cancer cells, this up-regulation of ORAI3 did not bestow an
ability to contribute to SOCE, which is apparent in ERα-positive MCF-7 breast cancer cells where
ORAI3 silencing suppresses SOCE [28,29]. We also did not observe any ORAI3 siRNA sensitive
increases in [Ca2+]CYT induced by arachidonic acid in MDA-MB-468 cells after hypoxia (data not
shown), suggesting that the increased ORAI3 levels did not promote an arachidonic acid-sensitive
ORAI1/ORAI3 heteromeric channel phenotype. Consistent with the absence of major hypoxia-induced
changes in the nature of Ca2+ signaling mediated by ORAI3, and the insensitivity of HIF1α induction
to ORAI3 silencing, the effects of ORAI3 silencing on changes induced by hypoxia were subtle. Our
data demonstrate ORAI3 is not a global regulator of responses to hypoxia. However, the ability of
ORAI3 but not ORAI1 silencing to attenuate EGFR phosphorylation induced by hypoxia suggested
that specific events in cancer cells activated by hypoxia are fine-tuned by ORAI3. Whether a direct
physical interaction occurs between ORAI3 and EGFR to modulate EGFR phosphorylation and/or
a localized gradient of calcium via ORAI3 mediated Ca2+ influx contributes to autophosphorylation
should be the focus of future studies. Such studies would help define the role of ORAI3 in breast
cancer cells that express EGFR.
Our RNA-Seq experiments assessing the consequences of ORAI3 silencing on alterations in
gene expression induced by hypoxia in MDA-MB-468 basal breast cancer cells further identified
specific functions that may be regulated by ORAI3 in basal breast cancers. Gene ontology classified
these changes as the suppression of processes related to cell migration and inflammatory/immune
responses. However, ORAI3 silencing did not suppress single cell migration during hypoxia in our cell
model. This lack of correlation may be evidence that ORAI3 is not a driver of cell migration in basal
breast cancers, but rather is a fine-tuner of cancer cell migration in some in vivo contexts, through
changing the suite of expressed genes in response to specific microenvironmental factors. These
ORAI3-sensitive genes may play important roles as breast cancer cells escape the hypoxic primary
tumor microenvironment. Future studies should also assess the potential opportunities presented
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by ORAI3 silencing/inhibition to alter inflammatory and immune responses in breast cancer. The
important role of ORAI3 in the regulation of the transcription of genes up-regulated by hypoxia
(despite its inability to attenuate HIF1α induction) is evidenced by the pronounced suppression of
placental growth factor (PGF) induction by hypoxia. PGF is a member of the vascular epidermal growth
factor (VEGF) family, with identified roles in tumor angiogenesis and inflammatory pathways [63].
It is specifically interesting to note (given our identification of ORAI3 regulation of both migratory
and immune/inflammatory pathways by hypoxia) that PGF is believed to reprogram the tumor
immune microenvironment and contribute to obesity-promoted breast cancer progression [64]. Our
identification of the regulation of PGF by ORAI3 during hypoxia was somewhat surprising, given
reports that in MDA-MB-231 basal breast cancer cells, hypoxic induction of PGF is HIF-dependent [65];
however, PGF induction by hypoxia in this investigation was suppressed by simultaneous silencing of
both HIF1α and HIF2α and hence this is an area for further study. Furthermore, whether the regulation
of EGFR in hypoxia by ORAI3 controls the expression of specific genes, as is the case for TRPC1 in this
cell line [61], could be the focus of future studies. Our observation of poorer RFS in some breast cancer
subtypes with high ORAI3 and low ORAI1 levels, is reflective of the association between the ORAI1
activators STIM1/STIM2 in basal breast cancers, where high STIM1/low STIM2 was associated with
poorer survival [11]. The potential importance of the ORAI3/ORAI1 heteromeric channel should now
be explored in basal breast cancers and TNBCs, as has been assessed in prostate cancer [26].
5. Conclusions
These studies have defined the remodeling of ORAI1 and ORAI3 in breast cancer molecular
subtypes. Elevated ORAI1 is a feature of basal breast cancers that are also defined by lower levels
of ORAI3. However, ORAI3 is inducible by hypoxia in basal breast cancer cells and other cancer cell
lines. In contrast to its major role in the proliferative and invasive properties of ERα-positive breast
cancer cell lines, the contribution of ORAI3 to ERα-negative breast cancer cell lines is more specific.
ORAI3 appears to be a modulator of specific processes involved in the regulation of cell migration and
inflammatory/immune pathways in response to hypoxia.
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